JB Chemicals Share Price Target 2026, 2027, 2028, 2029, 2030

JB Chemicals share price today

JB Chemicals & Pharmaceuticals (NSE: JBCHEPHARM) is the case study Indian pharma PE deals aspire to. KKR bought control in 2020, professionalised everything, pushed the portfolio chronic — Cilacar (calcium-channel blocker) and Rantac lead a brand stable that outgrows the market — and layered on a global CDMO franchise in medicated lozenges that quietly dominates its niche. KKR has since exited; the discipline stayed.

The economics: 25.5% ROCE, 26.7% operating margins, zero debt, and brands that compound like consumer staples. At 53.8×, our universe tags it wait — a superbly run franchise whose price already salutes the execution.

Chronic brands plus a hidden CDMO

Chronic therapies (cardiac, gastro) mean repeat prescriptions for years — the annuity end of Indian pharma — and JB’s flagship brands keep gaining prescriber share. The lozenges CDMO is the differentiator: global pharma outsources cough-and-throat manufacturing to few qualified players, and JB is among the world’s largest, adding dollar revenue with contract stickiness. Management guides both engines with the kind of capital discipline private equity institutionalised.

Watch-items: NLEM pricing actions on flagship molecules, integration of acquired ophthalmology/probiotic brands, lozenges client concentration, and the multiple — quality is proven; cheapness is not.

The numbers

From our research universe snapshot (5 Aug 2026):

Metric	Value
Market cap	₹38,677 Cr
P/E (TTM)	53.8
EV/EBITDA	33.4
Operating margin	26.7%
ROE / ROCE	18.9% / 25.5%
Debt to equity	0.00
Sales CAGR (5y)	15.2%
Profit CAGR (5y)	12.4%
Promoter holding	48.8%
EPS (TTM)	₹44.75

JB Chemicals share price target 2026 to 2030

EPS base ₹44.75 (TTM). Bear: chronic growth slows and the multiple mean-reverts — 8% growth at 32×. Base: brand outperformance plus CDMO wins — 13% growth at 43×. Bull: acquisitions compound and lozenges scale — 17% growth at 54×.

Year	Bear (32×, +8%)	Base (43×, +13%)	Bull (54×, +17%)
2026	₹1,545	₹2,175	₹2,825
2027	₹1,670	₹2,455	₹3,310
2028	₹1,805	₹2,775	₹3,870
2029	₹1,950	₹3,135	₹4,530
2030	₹2,105	₹3,545	₹5,300

From ₹2,409, the base case is ≈ +47% over four and a half years plus a ~1% yield. The bear case is −13%: chronic-brand franchises deflate gently. The range below converts gentle deflation into a proper entry.

Reasons to own JB Chemicals (at the right price)

1. Chronic-heavy brand stable — Cilacar and Rantac compound like staples, not drugs.
2. The global lozenges CDMO is a niche monopoly hiding inside a domestic pharma.
3. Zero debt, 25.5% ROCE, and PE-institutionalised capital discipline.
4. Post-KKR management has a proven bolt-on acquisition playbook.
5. Margin trajectory (26.7% OPM) still climbing with chronic mix.

The risks: 54× prices years of flawless execution, one NLEM entry on Cilacar would sting, and CDMO revenue concentrates among few global clients.

Should you buy at the current price?

The live buy range below is for members — where proven quality meets a defensible price.

FAQ

What is the JB Chemicals share price target for 2030? Base case ≈ ₹3,545 (43× on 13% compounded growth), bear ≈ ₹2,105, bull ≈ ₹5,300. Arithmetic above.

What changed under KKR’s ownership? Portfolio shifted toward chronic therapies, brand marketing was professionalised, capital allocation became disciplined, and the CDMO was scaled — the playbook survived KKR’s exit.

What is the lozenges CDMO business? JB manufactures medicated lozenges (cough, throat, nicotine) under contract for global pharma brands — one of the largest such manufacturers worldwide, with sticky, dollar-denominated revenue.

When are JB Chemicals’ next results? Track the exact date on our results calendar.

---

This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.